Locally Recurrent Rectal Cancer QoL Is Valid Patient-Reported Outcome Measure
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, June 9, 2023 -- A new locally recurrent rectal cancer (LRRC) quality of life (QoL) measure is a valid patient-reported outcome measure (PROM), according to a study published in the May issue of eClinicalMedicine.
Deena P. Harji, M.B.B.S., Ph.D., from the University of Leeds in the United Kingdom, and colleagues developed a disease-specific, psychometrically robust, and validated PROM for use in LRRC. A total of 117 adults in the United Kingdom and Australia with an existing or previously treated LRRC within the last two years completed the proposed LRRC-QoL, European Organisation for Research and Treatment of Cancer Quality of Life-C29 (EORTC QLQ-CR29), and Functional Assessment of Cancer Therapy-Colorectal (FACT-C) questionnaires. Nine multi-item scales (health care services, psychological impact, pain, urostomy-related symptoms, lower limb symptoms, stoma, sexual function, sexual interest, and urinary symptoms) and three single items were included in the LRRC-QoL measure.
The researchers found that overall reliability was supported by Cronbach's Alpha and Intraclass correlation values of >0.7 across the majority of scales. Validity was convergent between the LRRC-QoL pain scale and FACT-C Physical Well Being scale; LRRC-QoL psychological impact scale and EORTC QLQ-CR29 Body Image scale and the FACT-C Emotional Well-Being scale; and LRRC-QoL urinary symptoms scale and EORTC QLQ-CR29 Urinary Frequency scale. For gender, disease location, treatment intent, and recurrent disease, known-groups validity was demonstrated.
"The LRRC-QoL has the potential to transform outcome assessment in locally recurrent rectal cancer. In clinical practice, the LRRC-QoL will be able to quantify patient symptoms, experience, and overall satisfaction," a coauthor said in a statement. "This will lead to the disclosure and identification of potential issues not routinely reported and will aid the early detection and subsequent monitoring of symptoms."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
Digestive Disease Week, May 18-21
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.